Which Endpoints Matter Most in Transthyretin Amyloid Cardiomyopathy Trials? Are We Comparing Apples to Apples?

episode

Keeping Current CME not yet transcribed

▲ 0

Transcript

This episode hasn't been transcribed yet Upvotes decide what gets transcribed next — 0 so far. Sign in to upvote

Related

recent transcribed audio

ICYMI: Teresa & Melissa Reunite, Whitney Gets Real & Taylor Wants It on Camera 29 min · 28 Sep 2026 · Two Ts In A Pod with Teddi Mellencamp and Tamra Judge

Café com Deus Pai | Vai dar certo 3 min · 28 Sep 2026 · Café Com Deus Pai | Podcast oficial

Sam Morril's Guide to NYC! 1h 5m · 28 Sep 2026 · Are You Garbage? Comedy Podcast

How to Stop Living Paycheck to Paycheck & Finally Get Ahead 1h 8m · 28 Sep 2026 · The Mel Robbins Podcast

Matthew McConaughey & Woody Harrelson 1h 4m · 28 Sep 2026 · Conan O’Brien Needs A Friend

What Is a Covenant? 26 min · 28 Sep 2026 · Renewing Your Mind

Report any issue

Source

Recorded26 Mar 2024

Publisherkeepingcurrentcme.libsyn.com ↗

Handlerec:4299731

Show notes

Do you know how to interpret the results of recent phase 3 clinical trials in patients with transthyretin amyloid cardiomyopathy (ATTR-CM)? Credit available for this activity expires: 3/22/25 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/1000444?ecd=bdc_podcast_libsyn_mscpedu

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Sign in